Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nocentini, F
Right arrow Articles by Tura, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nocentini, F
Right arrow Articles by Tura, S
Haematologica, Vol 79, Issue 6, 546-549
Copyright © 1994 by Ferrata Storti Foundation


Clinical Trial

Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data

F Nocentini, L Gugliotta, L Catani, N Vianelli, S Baravelli, V Martelli, and S Tura

Hematology Institute L. & A. Seragnoli, University of Bologna, Italy.

The hemostatic toxicity of low dose L-asparaginase from Erwinia carotovora (Erwinase) has been reported to be negligible in adult patients with acute lymphoblastic leukemia (ALL); conversely, no consistent data have been obtained when Erwinase is administered at intermediate doses. We report preliminary clinical and laboratory hemostatic data from 10 adult patients with ALL treated during induction phase with intermediate doses of Erwinase (20,000 IU/m2s.c. every other day, for a total of six administrations). No thrombotic or hemorrhagic events were registered and the mean values of PT, aPTT, fibrinogen, antithrombin and D-dimer did not change during treatment. Only one patient showed a decrease of antithrombin (48% on day 8) requiring temporary suspension of Erwinase therapy. These data suggest that intermediate doses of Erwinase also have negligible hemostatic toxicity in adult patients with ALL.


This article has been cited by other articles:


Home page
BloodHome page
V. Caruso, L. Iacoviello, A. Di Castelnuovo, S. Storti, G. Mariani, G. de Gaetano, and M. B. Donati
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients
Blood, October 1, 2006; 108(7): 2216 - 2222.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1994 by the Ferrata Storti Foundation.